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The Mechanism Behind Adjuvants 
The immune system is characterized by two types of responses: the innate and the 
adaptive. The innate immune response is a quickly activated, general defense mechanism that 
deals with the identification and destruction of pathogens that enter the body and preventing 
them from spreading in the body. If the innate immune system is unsuccessful in destroying the 
pathogens, the adaptive immune system activates and follows with defenses that take a longer 
time to respond, but target pathogens more accurately.3 The advantage of developing adaptive 
immunity is that the first time the body comes into contact with a pathogen it may take a few 
days but any following infection by the pathogen will be dealt with more quickly. Adaptive 
immune responses can react faster than those of the innate defense, if the antigen is already 
known, and an infection with this pathogen a second time around may have milder symptoms or 
may not even be noticed by the infected person. A technique biomedical engineers are 
researching into to increase the magnitude of adaptive immune responses from a vaccine and 
produce an effective form of immunity against specific pathogens, are the use of adjuvants.  
Adjuvants are any substance that is formulated as part of a vaccine to enhance its ability 
to induce protection against infection.3 Adjuvants have shown the ability to prolong antigen 
exposure to dendritic cells (DCs) and induce their maturation. DCs act as a messenger between 
the innate and adaptive immune systems and are essential in the propagation of the immune 
cascade. Mature DCs are cells designed to initiate contact with and activate surrounding immune 
cells such as T cells, natural killer cells, etc., which is required for the induction of potent and 
long-lasting immunity. In the event of a pathogen invasion, DCs detect invading microbes via 
toll-like receptors (TLRs). TLRs expressed on membranes of leukocytes (also referred to as 
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white blood cells), such as dendritic cells, detect by recognizing pathogen-associated molecular 
patterns (PAMPs) that are expressed on infectious agents. When TLRs are activated, DCs 
produce cytokines to induce the immune cascade for the development of effective immunity 
against the pathogen.2  
Cytokines are chemical substances, such as chemokines, interferons, and interleukins, 
secreted by cells from the immune system that allow for cell-to-cell communication with one 
another to initiate and regulate the immune response.9 For example, IFN-β is an interferon 
produced by dendritic cells that helps in detecting the effects adjuvants have by indicating when 
the TLRs have been stimulated and NF-κB is activated. To enhance the body’s immune response 
to a pathogen, biomedical engineers are exploring adjuvants as an addition to vaccines to boost 
adaptive immune responses and elicit desired responses, including cytokine production. Utilizing 
adjuvants will aid in the development of improved, more effective vaccines that can aid in the 
production of a higher quantity of antibodies, the stimulation of more effective responses, and 
longer-lasting protection by activating TLRs on the dendritic cells.  
Adjuplex Immune-Activation & Utilization 
Adjuplex is a novel adjuvant comprised of lecithin and carbomer homopolymer.11 
Carbomers are a species of cross-linked polyacrylic acids that are already used in the biomedical 
industry as a stabilizer and thickening agent, and they demonstrate the ability to stimulate a 
strong T-cell response and a higher adaptive immune response than to an antigen alone. Lecithin 
is a biocompatible, naturally occurring surfactant found in biological membranes of things like 
soybeans or egg yolk. Lecithin also has beneficial properties as an emulsifier, stabilizer, and 
dispersing agent. Studies using Adjuplex show that when used as an adjuvant, it activates and 
alters antigen uptake, processing, and presentation. Additionally, Adjuplex has been shown to 
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trigger rapid leukocyte recruitment, pro-inflammatory cytokine secretion, and antigen capture by 
monocytes. Used alone Adjuplex has the potential to be an effective adjuvant.  
It is important to observe the response the adjuvants produce when introduced to a system 
via vaccine because there can be issues with autoimmunity if T-cells are not regulated, or, as this 
research paper will later discuss, certain adjuvant combinations can have a subtractive response 
where one adjuvant may turn off the other adjuvant’s response. Because adjuvants act on 
dendritic cells and induce effects that increase antigen immunogenicity, biomedical engineers are 
experimenting with different adjuvant doses and combinations to optimize the responses they 
produce and identify whether there is synergistic or suppressive immune-activation. Synergistic 
immune-activation is the phenomenon where the combination of two adjuvants that induce an 
immune response produce a higher response than they would individually. Suppressive immune-
activation is the opposite phenomenon where the combination of two adjuvants that would 
individually produce an immune response would inhibit the response. Although it has shown to 
yield potentially synergistic adaptive immune response and elicit strong T- and B-cell response, 
there haven’t been many studies looking at the interaction between Adjuplex and other adjuvants 
when combined.5 
In addition, although Adjuplex displays several characteristics that classify it as an 
adjuvant, it has shown signs of toxicity at various doses at injection sites in mouse studies.1,6 One 
way that we would like to deal with this issue and make Adjuplex more effective is to use 
particles as a delivery method. Nanoparticles and microparticles are a drug delivery method 
commonly used in pharmaceutical sciences and nanotechnology for encasing or carrying 
therapeutic agents to provide a targeted and controlled release therapy. Using 
nano/microparticles as a drug delivery system can have several benefits: they allow co-delivery 
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of antigens and adjuvants, enhance T-cell expansion and functionality, stimulate the formation of 
germinal centers, and assuage toxicity in vaccines.9  
Collectively, we would like to look at different doses of Adjuplex to observe its toxicity, 
find an optimal dose of Adjuplex, observe cytokine production with the delivery of Adjuplex-
adjuvant combinations, and experiment with the loading efficiency of these adjuvant 
combinations in nanoparticles for delivery and for vaccine optimization.  
Literature Review 
Adjuvants, substances added to boost the effects of vaccines, enhance adaptive immunity 
to experimental antigens by a variety of these mechanisms and pathways.3 Adjuplex is a novel 
carbomer-lecithin-based adjuvant, and both the carbomer and lecithin aspects of Adjuplex aid in 
its classification as an adjuvant. Carbomers, a species of cross-linked polyacrylic acids with long 
and broad uses in biomedicine, have been evaluated as experimental adjuvants in veterinary 
vaccines. A report by Weggman demonstrates that biodegradable carbomers are not harmful to 
mammals and stimulate a more robust immune response than that with antigen alone.11 
Meanwhile, due to lecithin’s properties as an emulsifier, stabilizer, antioxidant, and dispersing 
agent, it is utilized throughout the pharmaceutical industry for drug and vaccine delivery.11  Both 
of these characteristics support the potential that Adjuplex has as a novel adjuvant for human 
vaccines, but there is some conflicting data on how effective Adjuplex can be in relation to or in 
combination with other adjuvants, implications of toxicity on the response, and the mechanisms 
behind Adjuplex’s ability to produce an immune response.  
Moreover, the discovery of toll-like receptors (TLRs) and the identification of TLRs as a 
signaling receptor for adjuvants has allowed for a better understanding of how adjuvants function 
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in regard to induction of innate and adaptive immune responses. With this, there are 
characteristics or responses that are used to characterize whether something is an adjuvant and to 
map out the mechanisms they use to achieve a response. For instance, retinoic acid-inducible 
gene 1 protein (RIG-I, also referred to as PUUC) participates in the recognition of single- and 
double-stranded RNA viruses and leads to the production of an appropriate cytokines and 
chemokines. Researchers can look at the release of cytokines and chemokines to identify whether 
RIG-I stimulates an antiviral state and drives the adaptive immune system toward an efficient, 
specialized response against an infection.  
In addition, interferons, a subcategory of cytokines, and helper T-cells (Th1) can be used 
to look at long-term immune responses. Type I-IFN, activated by RIG-I, participates in NK cell 
activation, regulation of effector and memory T-cells, and B-cell activation for reoccurring or 
long-term exposure to an antigen.8 Currently, some studies are being done to learn more about 
the immune response Adjuplex produces. In Weggman’s research paper, they found that 
Adjuplex elicits a strong, balanced adaptive immune response and can drive potent antibody 
production that is protective against influenza virus challenge.11 Also, when looking solely at the 
carbomer aspect of Adjuplex, carbomers induced its own form of systemic adjuvant activity 
through strong pro-inflammatory type-1 T-cell (Th1) polarization. They investigated potential 
pathways of immune activation by carbomers in comparison with another well-characterized 
adjuvant, and they concluded that carbomers may mediate its adjuvant activity via novel 
mechanisms.  These mechanisms include antigen-presenting cell activation, Th1 induction, rapid 
leukocyte recruitment, pro-inflammatory cytokine secretion, and antigen capture by 
inflammatory monocytes.4 Therefore, the constituents of Adjuplex alone prove to invoke an 
immune response which is what classified it as an adjuvant, however, Adjuplex has been 
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compared to only one or two commonly used adjuvants. Therefore, even though it produces an 
immune response, it is unknown to what degree it produces one along the spectrum of adjuvants.  
On a larger scale, researchers can look at specific organs or the blood to make 
conclusions about the responses adjuvants have on the immune system as a whole. Results from 
a paper by Holbrook show that a vaccine with R848 adjuvant induces high-level of cell-mediated 
responses in primate neonates that result in increased virus clearance and reduced post-challenge 
compared with the nonadjuvanted virus vaccine. To make this conclusion, researchers obtained 
blood samples and analyzed antibody titers. This references the number of antibodies within the 
blood and it correlates with the strength of the immune response.6 Additionally, cells can be 
isolated from organs, including lymph nodes, spleens, and bone marrow from bones. These cells 
can be used to look at T-cell activation and memory in response to a treatment and its 
effectiveness in creating an adaptive immune response. This technique was similarly used to 
characterize Adjuplex-induced immune response in a paper by Gasper. They reported that mice 
immunized with Adjuplex-supplemented intranasal vaccines generated cytotoxic T lymphocyte 
(CTL) responses and stimulated alterations in the frequency of dendritic cells in the lymph 
nodes. In addition, they reported that Adjuplex enhanced the ability of dendritic cells to promote 
an antigen-induced increase of naive CD8 T-cells by modulating antigen uptake, intracellular 
localization, and the rate of processing.5 To classify how effective Adjuplex is as an adjuvant, a 
focus must be placed on recognizing the mechanisms that Adjuplex uses to produce an immune 
response throughout the entire body and to what degree. Researchers have looked at initial 
immune response but have failed to follow through and examine extensively the effects Adjuplex 
has on the immune cascade over an extended period across the entire body.  
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Furthermore, when looking at the risks versus benefits of adjuvants in vaccines, toxicity 
is a factor that is considered due to the damage it can cause to local tissue and the potential for 
inflammatory reactions at injection sites. For example, Monophosphoryl lipid A (MPLA), a low-
toxicity derivative of the lipid A region of lipopolysaccharide (LPS), is commonly used as an 
adjuvant in mice and has shown to induce a strong Th1 response, suggesting that MPLA 
improves vaccine immunogenicity by enhancing antigen presenting T- and B-cells. While the 
toxicity associated with LPS prohibited its potential clinical use, MPLA is being developed as a 
vaccine adjuvant and is promising due to its low toxicity. Results from a paper from Beatty 
observed there was toxicity at the site of injection at higher doses of Adjuplex.1 This data 
indicates that the dose of Adjuplex plays a role in toxicity levels and in the efficacy of producing 
an immune response, but there currently is a lack of research on appropriate Adjuplex doses to 
be used in vaccines. Similarly, in Weggman’s research paper, they indicated that Adjuplex is 
well tolerated in mice.11 However, other than quick eye observations of the injection sites for 
irritation, there was no additional data evaluating Adjuplex’s toxicity.  
A potential solution to the toxicity issue with the use Adjuplex, which we will discuss 
later on in this paper, is the use of nano/microparticles (NPs/MPs). NP/MP delivery systems for 
antigens have shown to be very useful in conjunction with adjuvants. NPs/MPs loaded with 
adjuvants have shown the capability to promote both cellular and humoral immune responses. 
For instance, mice immunized with NPs and MPLA showed broader humoral responses and the 
combination lasted more than one year in mice at lower doses compared to conventional 
adjuvants. Also, the researchers from this paper examined several components of the B-cell 
response and found that NPs/MPs promoted germinal center (GC) formation at low doses of 
antigen, that GCs gravitated towards clusters of NPs accumulating in the draining lymph nodes 
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over time, and enhanced the expansion of follicular helper T cells (Tfh).9 Therefore, the use of 
NPs/MPs can be a promising solution to toxicity issues with Adjuplex while also promoting 
desired adaptive immune responses.  
Moreover, this paper will address the Adjuplex combined with NPs/MPs, but it will also 
observe the immune response produced by Adjuplex combinations with other known adjuvants. 
In cases of synergistic immune responses, studies have shown that combination adjuvants can 
produce the desired, boosted immune response by activating different pathways. In the case of 
Adjuplex, flow cytometry studies revealed that Adjuplex recruited dendritic cells (DCs), 
monocytes, and neutrophils based on cytokine and chemokine secretion from these cells. 
However, Adjuplex neither triggered classical maturation of DCs nor activated NF-KB from 
pathogen recognition receptors (PRRs), suggesting the use of a different mechanism or pathway 
from previously reported PAMP-activated innate immunity cascade pathways followed by other 
adjuvants.11 Therefore, since Adjuplex follows other immune pathways than traditional 
adjuvants, it will be difficult to predict what immune responses can occur in combining Adjuplex 
with other adjuvants. For instance, in Holbrook’s paper about R848, the addition of a second 
TLR agonist (flagellin) to R848, a TLR agonist itself, did not enhance vaccine protection, 
suggesting that combinations of TLRs that provide increased efficacy have to be determined 
experimentally.6 As a result, there is the possibility that adding another adjuvant or agonist may 
not enhance protection as we intuitively think it will while Adjuplex’s mechanism remains 
unclear. 
The current study addresses the lack of knowledge there is on the implications of 
combining Adjuplex with other common adjuvants, dose-dependent toxicity, and the 
mechanisms that Adjuplex uses to produce an immune response as a novel adjuvant. Using in 
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vitro methods, this study expands on Adjuplex toxicity from variable dose quantities and 
documents a possible dose that is reasonable for usage in vaccines. Additionally, we assessed 
cytokine production using Adjuplex in combination with other known adjuvants to conclude 
whether the addition of Adjuplex can produce a stronger immune response that can compete with 
other tested adjuvant combinations. More importantly, synergy between Adjuplex and other 
adjuvants is determined since current literature has shown that Adjuplex produces immune 
responses by activating different pathways than other adjuvants.  After looking at how much 
activation Adjuplex causes when introduced to a system, methods such as using particles as a 
delivery system were implemented to observe whether the use of particles assists in the 
activation of a stronger immune response. Finally, the study will provide information towards 
determining the best way to use Adjuplex to customize vaccines to their pathogens so that the 
vaccine will produce the response needed based on the disease or condition the pathogen causes.  
Methods and Materials 
RAW-Blue Cell Treatment 
 RAW-Blue cells were kept in a medium consisting of DMEM medium (containing 4.5 
g/L glucose and 2mM L-glutamine), 10% characterized fetal bovine serum (FBS), 1% penicillin-
streptomycin (Pen-Strep) and 100 μg/mL of Normocin. Cells were fed using media 
supplemented with 100 μg/μL of Zeocin. When cells reached 90% confluence, media was 
aspirated out of flask and cells were dislodged from the bottom of the flask to prepare for 
splitting. RAW-Blue cells were centrifuged, resuspended in media, counted using a Countess 
Cell Counter, and split into flasks or plated at the appropriate concentrations for experiments. 
Cell Culture 
All animal experiments were approved by The Institutional Animal Care and Use 
Committees (IACUC) at Georgia Institute of Technology (Atlanta, GA). Bone marrow-derived 
cells (BMDCs) were generated from bone marrow of C57 BI/6 mice. Briefly, BMDCs were 
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isolated from tibias and femurs of mice and cultured in RPMI 1640 Glutamax medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% characterized FBS, Pen-Strep, sodium 
pyruvate, beta-mercaptethanol, and 20 ng/mL mouse granulocyteemacrophage colony-
stimulating factor (GM-CSF) for 6 days. On day 2 and 4, the medium was replaced with new 
medium containing GM-CSF. On day 7, loosely adherent DCs were harvested and used for 
further experiments. 
Cell Treatment 
Harvested DCs are plated in a 96-well plate with 300,000 cells per well (150 uL per 
well). The plate is put to incubate in 37°C and undisturbed for at least 2 hours to allow cells to 
adhere. Formulations of adjuvants are made. For MPLA, the stock solution (1 mg/mL in DMSO) 
is diluted in media to a concentration of 10,000 ng/mL, and for CpG, the stock solution (1.05 
mg/mL in DI H2O) is diluted in media to a concentration of 10,500 ng/mL. NP RIG-I involved 
the making and loading of the nanoparticle. NP RIG-I was diluted to a 25% concentration. 
Adjuplex is diluted to a 4% concentration in media. To make the combination adjuvant or 
nanoparticle formulations, Adjuplex was kept at a 4% concentration in media and the other part 
of the forumulation came from the diluted stock solutions mentioned earlier. From those 
formulations, 50 uL were added to the cells in the 96-well plate, and left to incubate at 37°C for 
24 hours. 
Variable Loading of Nanoparticles 
 To load the nanoparticles, R848-PLGA NPs were measured out and resuspended in Na-P 
loading buffer to obtain a concentration of 5 mg/mL. The resuspended nanoparticles were 
sonicated in a bath sonicator for five minutes before adding the different amounts of adjuvant 
based on concentration. Then, the vials were rotated end-to-end for at least twelve hours before 
being used. RNA loading efficiencies for all nanoparticles ranged between 80-90%. 
Microplate Reader 
Analyses were performed using BioTek Synergy HTX Multi-Mode Microplate Reader. 
In preparation for reading, RAW-Blue cells were rinsed in sterile PBS and diluted in test 
medium. Test medium contained RAW media with Normocin, Zeocin, heat-inactivated fetal 
bovine serum (FBS), and Penicillin Streptomycin (Pen-Strep) as instructed in RAW-Blue cell 
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datasheet for cell maintenance and activation. Diluted formulations of RAW-Blue cells and 
nanoparticle samples were added to a flat plate with QUANTI-Blue substrate provided with 
RAW-Blue cells and incubated for thirty minutes to stimulate activation. The plate was read and 
analyzed using Gen5 software at 24-, 48-, and 72-hour time points. This was also used to take the 
IL-18 and IL-1β ELISA data. ELISA procedures are similar to Luminex.  
Luminex 
A Luminex assay with diluted samples of RAW-Blue cells from InvivoGen in San Diego, 
CA and nanoparticles loaded with R848 and varying amounts of PUUC was performed. Another 
Luminex assay with treated samples of BMDCs with several soluble adjuvants and soluble 
adjuvant combinations was also performed later on. Samples were either used as is or diluted 5-
fold in BMDC media and placed in flat bottom plate with magnetic beads. Samples were plated 
to fill four wells or eight wells down the column (depending on the experiment) to observe 
variability between samples. Diluted detection antibodies, tertiary antibodies, and streptavidin-
PE (SA-PE) were added according to guidelines provided in Invitrogen ProcartaPlex Mouse 
Basic kit. Then, magnetic beads were resuspended using reading buffer before being put into the 
machine. The assay was performed with the purpose of measuring the amount of interferon beta 
(IFN-β), a cytokine, produced as a result of TLR activation by adjuvants.  
Flow Cytometry 
 On day seven, BMDCs were plated at 300,000 cells/ mL per well in a 96 well plate and 
treated with various soluble adjuvants. After 24 hours of treatment, the BMDCs stuck on the 
plate after the supernatant was removed were scraped, resuspended in FACS buffer, and 
transferred into FACS tubes. Samples were incubated in diluted FC-Block for five minutes and 
then fluorescent antibody markers for 30 minutes in the dark at 4°C. Finally, the BMDCs were 
washed with FACS buffer, incubated in Biolegend fixation buffer, and analyzed using a BD 
Accuri flow cytometer. FloJo software was used for analysis. Samples were gated, and 
compensation was applied. Once the desired population was isolated, percentages and mean 






I. Synergistic Immune-Activation 
RAW-Blue cells are derived from RAW 264.7 macrophages and express almost all 
TLRs. When adjuvants are introduced to the RAW-Blue cells, the activated TLRs induce 
signaling pathways which lead to the activation of NF-κB, an important component for 
controlling cytokine production. Along with the activation of NF-κB, they secrete a secreted 
embryonic alkaline phosphatase (SEAP) gene which, combined with QUANTI-Blue substrate, 
makes the RAW-Blue cells turn blue and allows easy detection and measuring as shown in 
Figure 1 and 2. Using RAW-Blue cells, we looked at what synergistic activation TLRs 
influenced by adjuvant dose quantities and common adjuvant combinations. This concept is 
established now and used later on to defined whether Adjuplex produces a synergistic immune 
response. 
               
Influence of NP- R848-PUUC Loading Dose on NF-κB Production  
Since NF-κB is an indicator that the adjuvant activated TLRs on the RAW-Blue cells, 
different doses of PUUC loaded in NP-R848 were tested to explore the effect increasing 
Figure 2: Picture showing example of 
plate layout and blue color after assay 
incubated with QUANTI-Blue  
  
Figure 1: Diagram illustrating the cascade of 
activation within a RAW-Blue cell similarly 




increments PUUC loaded on NP-R848 would have on TLR activation in the cells. The RAW-
Blue cells with the nanoparticles were incubated in QUANTI-Blue substrate and run through the 
microplate reader to measure the SEAP levels, indicated by the absorbance or how blue each 
well turned. T-tests were performed to quantitatively analyze differences between the untreated 
control and the loaded NPs impact on NF-κB production. All samples displayed an increase in 
NF-κB production as shown in Figure 3. The mean value for the NP-R848-PUUC with 10 μg 
was the highest among all the doses. The two-tailed p-values (p<.05) indicate there was a 
statistically significant increase from the untreated after 72 hours. Therefore, we should expect to 
see an increase in TLR activation for adjuvant combinations that exhibit synergistic immune 
effects.  
Different Formulations of Adjuvants in Nanoparticles and its Effect on NF-κB Production 
Adjuvants are used to activate specific TLRs present in dendritic cells. Since no single 
adjuvant can induce all the protective immune responses, combinations of adjuvants have the 
potential to induce synergistic enhancement of immune responses that can be tailored to specific 
antigens found on pathogens. To explore this, RAW-Blue cells with NPs containing single, dual, 
and triple adjuvant combinations were incubated with QUANTI-Blue substrate and run through 
the microplate reader at 24- and 48-hour time intervals. T-tests showed that there were 
statistically significant increases (p<.05) between the untreated and NP-R848, NP-R848-PUUC, 
NP-R848-PolyIC, and NP-R848-PUUC-PolyIC (Figure 4). The p-values were similar between 
the NP-R848-PUUC, NP-R848-PolyIC, and NP-R848-PUUC-PolyIC combinations all being 
Figure 3: Results from 24-, 48-, and 72-hour time points of RAW-Blue cells NF-κB production. 




around 0.0002. Overall, these results illustrate how combinations of adjuvants are capable of 
producing synergistic, boosted immune responses.  
Measurement of IFN-β Production with Various NP-R848-PUUC Doses  
When an adjuvant is introduced to a cell, 
the TLR is stimulated and NF-κB is activated.  In 
addition, IFN-β is released out of the cell and can 
be measured by performing a Luminex assay. 
RAW-Blue cells were treated for 24 hours with 
NPs loaded with R848 and increasing increments 
of PUUC. Based on the data, there was an 
increase in IFN-β production in all the 
combination adjuvant samples. The NP-R848-
PUUC with 20 μg had a larger spread than the 
other doses. The NP-R848-PUUC with 10 μg 
seems to produce the highest and most stable 
amount of IFN-β than the other doses (Figure 5). 
Figure 4: Results from 24- and 48-hour time intervals for RAW-Blue cells NF-κB production 
induced by different adjuvant combinations. Each bar represents a well in the 96-well plate. Each 
plate had four samples of the same dose. 
Figure 5: Graph shows the spread and individual 




These results show that adjuvant combinations are 
dose-dependent, and this synergistic combination 
produced a boosted immune response.  
IFN-β Production After Soluble Adjuplex, Soluble 
MPLA, Soluble CpG, and NP RIG-I Combinations 
Treatment 
A Luminex assay was done with common 
adjuvants (MPLA and CpG), soluble RIG-I and 
nanoparticle RIG-I (NP RIG-I), and the newly 
obtained Adjuplex. Single adjuvants (soluble MPLA, 
CpG, and NP RIG-I) produced a response as expected, 
and the MPLA-CpG combination produced a higher 
amount of IFN-β than the single adjuvant treatments. 
This also correlates with previous data taken on these 
adjuvant combinations. However, Adjuplex alone and 
all combinations with Adjuplex produced almost no 
IFN-β (Figure 6). This was an unexpected result, and further testing was necessary to determine 
why these results were produced. Possibilities we theorized could be behind this was that the 
Adjuplex dose was too toxic and killed cells, which attributes to lower IFN- β production, or that 
the Adjuplex sample given to use may have expired.  
Soluble Adjuvant Treatment with Old and New Batch of 
Adjuplex  
First, a Live/Dead Stain was performed to observe 
whether low IFN-β production was due to cell death from 
Adjuplex toxicity. Figure 7 shows that, even at the highest 
concentration of Adjuplex tested, only about 25% of cells 
were dead. Therefore, we could conclude that lower IFN- β 
production from above was not due to low cell count from 
toxicity. Additionally, since higher doses of Adjuplex yield 
better results according to literature, we decided to continue 
Figure 6: Graph of the spread and individual points of 
IFN-β production of the supernatant of each treated 
sample of BMDCs after 24 hours. Samples included: 
Adjuplex 9/18, Adjuplex 9/18 with combination 
adjuvants and nanoparticles, MPLA alone, CpG alone, 
MPLA and CpG, and NP RIG-I. 
 
Figure 7: 7-AAD toxicity data 
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using the 1% concentration of Adjuplex in following 
experimentation. Next, collaborators who make the 
Adjuplex indicated that there could be a variation of 
toxicity between batches. Therefore, the Luminex 
assay for this round of experimentation included a 
batch of Adjuplex from October 2017 (10/17) and a 
newer batch from September 2018 (9/18). However, 
once again, single adjuvants (soluble MPLA and 
CpG) produced a response, the MPLA-CpG 
combination produced a higher amount of IFN-β than 
the single adjuvant treatments, and any combination 
with Adjuplex produced no amount of  IFN-β (Figure 
8). Therefore, we concluded there was no variation 
between the 10/17 batch and the 9/18 batch, and these 
theories could not provide a reason as to why Adjuplex 
was reacting this way.  
MTS Cell Proliferation Assay to Assess Cell Viability 
An MTS assay is used to assess cell 
proliferation, cell viability, and cytotoxicity so 
conclusions can be made about how Adjuplex affects the 
cell metabolic activity. The supernatant of BMDCs 
treated with single, double, and triple adjuvant 
combinations after 48 hours. Overall, we concluded 
from the results, shown in Figure 9, that Adjuplex was 




Figure 8: Graph of the spread and individual points of 
IFN-β production of the supernatant of each treated 
sample of BMDCs after 24 hours. Samples included: 
Adjuplex 10/17, Adjuplex 10/17 with combination 
adjuvants, Adjuplex 9/18, Adjuplex 9/18 with 
combination adjuvants, MPLA alone, CpG alone, and 
MPLA and CpG. 
 
Figure 9: Graph of the spread and individual points 
of absorbance of each treated sample of BMDCs after 




Percentages of Costimulatory Proteins Detected After Soluble Adjuplex and Adjuvant Treatment 
The treated BMDCs scraped from the wells and transferred to FACS tubes were analyzed 
by flow cytometry. The following markers were used to stain the cells: CD86, MHC I, and CD40 
protein. CD86 protein expression indicates potential for T cell activation. MHC I molecule 
expression indicates an increased potential for MHC I presentation of antigen. CD40 induces 
downstream effects of the immune cascade. In comparison with the untreated stained sample, 
CD86, MHC I, CD40 expression in all samples treated with Adjuplex showed an increase 
(Figure 10). These results illustrate that Adjuplex is producing an immune response, but that the 
markers we have been looking at do not represent the pathway Adjuplex uses. 
IL-18 and IL-1β Production with Adjuplex Combination Treatments 
 After doing some research into other pathways that Adjuplex may use to produce an 
immune response, we found the inflammasome pathway. An inflammasome is a sensor protein 
that can oligomerize into a pro-caspase-1 activating platform in response to PAMPs. The 
inflammasome pathway secretes proinflammatory cytokines, IL-18 and IL-1β. Therefore, to 
verify whether Adjuplex was activating the inflammasome pathway, we executed initial ELISA 
assays for these cytokines with Adjuplex and GLA, an adjuvant we had in hand. In both the IL-
18 and IL-1β graphs in Figure 11, the results show that both adjuvants alone were not that strong, 
but, in combination, they produced a stronger immune response through the inflammasome 
pathway.  
Figure 10: Graphs showing percentages of CD86, MHC I, CD40 protein expression taken from FloJo analysis 











Characterization of the type of adaptive immune response Adjuplex produces as an 
adjuvant is of critical relevance to the development of synergistic (and possibly suppressive) 
adjuvant combinations and optimization of vaccines. This thesis research contributed to the field 
of biomedical engineering by utilizing RAW-Blue cells to observe IFN-β and NF-κB production 
and make conclusions on the effects doses and combinations of adjuvants have on immune 
activation. In addition, Luminex assays, flow cytometry, and ELISA experiments were 
performed to examine Adjuplex, a novel adjuvant. From this data, we were able to learn more 
about the mechanism behind its ability to produce an immune response and how Adjuplex 
interacts with other adjuvants in combination. 
The experiments presented provides insight in another procedural technique in assessing 
synergistic activation or suppression of TLRs via IFN-β and NF-κB production. RAW-Blue cells 
were used to look at double and triple adjuvant combinations and gave a basis on IFN-β and NF-
κB production by adjuvants that were used to compare to the response Adjuplex produces.  
However, RAW-Blue cells still haven’t been used to assess whether Adjuplex activates and, if 
so, to what degree it activates the NF-κB signaling pathway. 
While investigations summarized in this thesis show that Adjuplex in combination with 
other common adjuvants such as MPLA and CpG decreases the production of IFN-β, this doesn’t 
indicate that Adjuplex is blocking immune response that those adjuvants typically induce. We 
Figure 11: Graphs showing IL-18 and IL-1β production after treatment with adjuvants and adjuvant combination. 




were able to show that there was synergy between Adjuplex and GLA when looking at cytokines 
produced in the inflammasome pathway. Therefore, future work will expand on this finding and 
experiments will focus on further validating this finding by looking at other markers in the 
inflammasome pathway. Another experiment that can be done is to move to animal studies and 
treat mice with genes along the immune cascade knocked out to narrow down the pathway 
Adjuplex uses. Additionally, Adjuplex has only been compared to several common adjuvants 
and one particle formulation. In following experiments, we would like to expand on adjuvant 
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